このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Can-Fite BioPharma マネジメント

マネジメント基準チェック /44

Can-Fite BioPharma'sの CEO はMotti Farbsteinで、 Aug2003年に任命され、の在任期間は 20.83年です。の年間総報酬は$ 467.00Kで、 66.4%給与と33.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0%を直接所有しており、その価値は₪ 43.12 。経営陣と取締役会の平均在任期間はそれぞれ20.8年と15.8年です。

主要情報

Motti Farbstein

最高経営責任者

US$467.0k

報酬総額

CEO給与比率	66.4%
CEO在任期間	20.8yrs
CEOの所有権	0.00008%
経営陣の平均在職期間	20.8yrs
取締役会の平均在任期間	15.8yrs

経営陣の近況

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Jun 19

Recent updates

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Jun 19

CEO報酬分析

Can-Fite BioPharma の収益と比較して、Motti Farbstein の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	US$467k	US$310k	-US$8m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$471k	US$298k	-US$10m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$484k	US$291k	-US$15m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$468k	US$313k	-US$15m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$13m
Dec 31 2019	US$277k	US$195k	-US$13m
Sep 30 2019	n/a	n/a	-US$11m
Jun 30 2019	n/a	n/a	-US$8m
Mar 31 2019	n/a	n/a	-US$7m
Dec 31 2018	US$331k	US$186k	-US$7m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$6m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	US$315k	US$242k	-US$6m

報酬と市場: Mottiの総報酬 ($USD 467.00K ) は、 IL市場 ($USD 436.82K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Mottiの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Motti Farbstein (60 yo)

20.8yrs

在職期間

US$467,000

報酬

Mr. Motti Farbstein serves as a Chief Operating and Financial Officer at Can-Fite BioPharma Ltd. since May 2005 and serves as its Chief Executive Officer since June 30, 2023. Mr. Farbstein served as Chief...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Pnina Fishman	Founder	18.8yrs	US$703.00k	0.018% $ 8.7k
Motti Farbstein	CEO and Chief Financial & Operating Officer	20.8yrs	US$467.00k	0.000080% $ 39.5
Sari Fishman	Vice President of Business Development	10.4yrs	US$373.00k	データなし
Ilan Cohn	Co-Founder & Director	29.8yrs	データなし	0.0089% $ 4.4k
Stephen A. Harrison	Member of Clinical Advisory Board & Consulting Chief Medical Officer	less than a year	データなし	データなし

20.8yrs

平均在職期間

65yo

平均年齢

経験豊富な経営陣: CANFの経営陣は経験豊富で経験豊富です（平均在職期間は20.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Pnina Fishman	Founder	18.8yrs	US$703.00k	0.018% $ 8.7k
Ilan Cohn	Co-Founder & Director	30.4yrs	データなし	0.0089% $ 4.4k
Stephen A. Harrison	Member of Clinical Advisory Board & Consulting Chief Medical Officer	no data	データなし	データなし
Nabil Hanna	Member of Scientific Advisory Board	no data	データなし	データなし
Yaacov Goldman	External Independent Director	6.8yrs	US$60.00k	データなし
Abraham Sartani	Independent Director	23.4yrs	データなし	データなし
Guy Regev	Independent External Director	12.9yrs	US$60.00k	0.0016% $ 800.4
Scott L. Friedman	Member of Clinical Advisory Board	no data	データなし	データなし
Arun Sanyal	Member of Clinical Advisory Board	no data	データなし	データなし
Yoseph Bornstein	Independent External Director	2.8yrs	データなし	データなし
Rifaat Safadi	Member of Clinical Advisory Board	no data	データなし	データなし
Kim Papp	Member of Clinical Advisory Board	no data	データなし	データなし

15.8yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: CANFの取締役会は経験豊富で経験豊富です ( 15.8年の平均在任期間)。

Can-Fite BioPharma マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Can-Fite BioPharma Ltd., Annual General Meeting, Jun 26, 2024

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Insufficient new directors

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Insufficient new directors

Recent updates

Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix

Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study

Can-Fite BioPharma Ltd., Annual General Meeting, Jun 26, 2024

New minor risk - Share price stability

Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.003 loss in 3Q 2022)

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Financial data availability

First half 2023 earnings released: US$0.004 loss per share (vs US$0.006 loss in 1H 2022)

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.003 loss in 1Q 2022)

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Insufficient new directors

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Second quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 2Q 2021)

Forecast to breakeven in 2023

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

First quarter 2022 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1Q 2021)

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel

Insufficient new directors

Can-Fite Biopharma Ltd. Announces It Is Developing A Topical Psoriasis Treatment with Piclidenoson, Its Phase III Psoriasis Oral Drug Candidate

Can-Fite BioPharma Ltd. Announces Top Line Data from its Phase III Comfort™ Study of Piclidenoson in Treatment of Moderate-To-Severe Plaque Psoriasis to Be Release in the Second Quarter of 2022

We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

Can-Fite BioPharma Ltd. Announces Pre-Clinical Studies with Skin Cells, Modeling Psoriasis in Humans

Can-Fite Biopharma Ltd Files Patent Applications for the Treatment of Various Advanced Solid Tumors

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Can-Fite Biopharma Ltd. Announces Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Can-Fite Biopharma Ltd. Commences Clinical Study for the Treatment of Canine Osteoarthritis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?

Can-Fite BioPharma Ltd. Completes Patient Enrollment in Phase III Psoriasis Study

Second quarter 2021 earnings released: US$0.006 loss per share (vs US$0.013 loss in 2Q 2020)

Can-Fite BioPharma Ltd Receives Notice of Patent Allowance in China for NASH Treatment

No longer forecast to breakeven

Can-Fite Biopharma Ltd. to Initiate Phase IIb Nash Study with its Drug Candidate Namodenoson

マネジメント基準チェック /44